The Relationship Between Psoriasis, Covid-19 Infection and Vaccination During Treatment of Patients Publisher Pubmed



Khanahmadi M^{1, 2} ; Khayatan D^{1, 2} ; Guest PC^{3, 4, 5} ; Hashemian S⁶ ; Abdolghaffari AH^{1, 2, 7, 8} ; Sahebkar A^{6, 9, 10} Show Affiliations
Source: Advances in Experimental Medicine and Biology Published:2023

Abstract

Since the outbreak of the COVID-19 pandemic in December 2019, scientists worldwide have been looking for a way to control this global threat. One of the most successful and practical solutions has been the development and worldwide distribution of the COVID-19 vaccines. However, in a small percentage of cases, vaccination can lead to de novo development or exacerbation of immune or inflammatory conditions such as psoriasis. Due to the immunomodulatory nature of this disease, people affected by psoriasis and other related skin conditions have been encouraged to receive COVID-19 vaccines, which are immunomodulatory by nature. As such, dermatological reactions are possible in these patients, and cases of onset, exacerbation or change in the type of psoriasis have been observed in patients administered with COVID-19 vaccines. Considering the rarity and minor nature of some of these cutaneous reactions to COVID-19 vaccination, there is a general consensus that the benefits of vaccination outweigh the potential risks of experiencing such side effects. Nevertheless, healthcare workers who administer vaccines should be made aware of the potential risks and advise recipients accordingly. Furthermore, we suggest careful monitoring for potentially deleterious autoimmune and hyperinflammatory responses using point-of-care biomarker monitoring. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.